TCCL Archive
Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival
TCCL Archive
Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis
TCCL Archive
Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL
TCCL Archive
Biomarker May Predict Prostate Cancer Metastases
TCCL Archive
Individualized Cancer Vaccines Show 90% Survival at 6 Months
TCCL Archive
Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial
TCCL Archive
Two Phase II Studies of Ibrutinib Deliver High Response Rates
TCCL Archive
NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent
TCCL Archive
Study: BRCA2-Negative Women Could Still Have High Risk
TCCL Archive
Velcade Addition Can Improve Graft-Versus-Host Outcomes
TCCL Archive
NCI CTEP Approved Trials For the Month of December
TCCL Archive
FDA Expands Nexavar Indication To Include Thyroid Cancer
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Science advocates organize march in DC to demand impeachment of RFK Jr.
- Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints
